Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Change in Working Capital: 2021-2025

Historic Change in Working Capital for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$3.6 million.

  • ProQR Therapeutics N.V's Change in Working Capital fell 392.95% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.8 million, marking a year-over-year increase of 90.77%. This contributed to the annual value of -$53.0 million for FY2023, which is 11616.84% down from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Change in Working Capital stood at -$3.6 million for Q3 2025, which was down 169.50% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's Change in Working Capital registered a high of $56.1 million during Q1 2023, and its lowest value of -$102.9 million during Q4 2023.
  • In the last 3 years, ProQR Therapeutics N.V's Change in Working Capital had a median value of -$3.8 million in 2025 and averaged -$7.9 million.
  • Within the past 5 years, the most significant YoY rise in ProQR Therapeutics N.V's Change in Working Capital was 1,366.01% (2023), while the steepest drop was 9,834.52% (2023).
  • ProQR Therapeutics N.V's Change in Working Capital (Quarterly) stood at $22.1 million in 2021, then tumbled by 104.68% to -$1.0 million in 2022, then tumbled by 9,834.52% to -$102.9 million in 2023, then spiked by 156.12% to $1.2 million in 2024, then crashed by 392.95% to -$3.6 million in 2025.
  • Its Change in Working Capital stands at -$3.6 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$7.1 million for Q1 2025.